Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Doi, T; Shitara, K; Naito, Y; Shimomura, A; Fujiwara, Y; Yonemori, K; Shimizu, C; Shimoi, T; Kuboki, Y; Matsubara, N; Kitano, A; Jikoh, T; Lee, C; Fujisaki, Y; Ogitani, Y; Yver, A; Tamura, K

Doi, T (reprint author), Natl Canc Ctr Hosp East, Kashiwashi, Chiba 2778577, Japan.

LANCET ONCOLOGY, 2017; 18 (11): 1512